TL;DR
This cross-sectional study of over 1,000 patients with type 2 diabetes (T2DM) reveals that hyperuricaemia is associated with a nearly four-fold increase in the risk of dyslipidaemia. Crucially, the researchers identified that serum uric acid (SUA) acts as a significant mediator—accounting for roughly 20% of the relationship—between insulin resistance and disrupted triglyceride metabolism.
What Problem Does This Paper Address?
Dyslipidaemia (abnormal lipid levels) is a major driver of cardiovascular complications in patients with T2DM, yet in regions like China, control rates for this condition remain alarmingly low (around 7%). While serum uric acid (SUA) is known to disrupt lipid metabolism in the general population, the relationship is far more complex in diabetic patients due to the confounding effects of insulin resistance, inflammation, and glucose-lowering medications (like SGLT2 inhibitors) that alter SUA excretion.
The authors sought to clarify whether SUA is independently associated with dyslipidaemia in T2DM and, more importantly, to identify an "optimal" SUA threshold that minimizes metabolic risk—a target that might differ from standard clinical definitions of hyperuricaemia.
Methods
The researchers conducted a cross-sectional analysis of 1,036 T2DM inpatients. They employed several sophisticated statistical techniques beyond standard correlation:
- Multivariate Logistic Regression: Used to calculate Odds Ratios (ORs) while adjusting for a wide array of confounders including age, BMI, HbA1c, eGFR, and specific medication types.
- Restricted Cubic Splines (RCS): A non-linear modeling approach used to visualize the dose-response relationship between SUA levels and dyslipidaemia risk.
- Mediation Analysis: Used to quantify how much of the effect of insulin resistance (measured via HOMA-IR) on triglycerides is actually "channeled" through SUA levels.
- Attributable Risk Calculation: To estimate the proportion of dyslipidaemia cases in the population that could theoretically be prevented if hyperuricaemia were eliminated.
Datasets
The study utilized a clinical dataset extracted from the electronic medical records of Jining Medical University (China) between January 2019 and July 2022.
- Initial Pool: 1,533 patients with diabetes.
- Final Cohort: 1,036 patients (after excluding Type 1 diabetes, minors, and those already on uric-acid-lowering therapy).
- Metrics: Included detailed biochemical markers (SUA, TC, TG, LDL-C, HDL-C, HbA1c, creatinine) and lifestyle data (smoking, drinking).
Key Insights and Ideas
- The "Middleman" Mechanism: The study provides evidence that SUA isn't just a bystander; it is a mediator. It elucidates 20.1% of the total relationship between insulin resistance and high triglycerides. This suggests that insulin resistance may drive up uric acid, which in turn disrupts lipid processing.
- The 320 µmol/L Inflection Point: While clinical hyperuricaemia is often defined as $\ge$ 420 µmol/L, the RCS analysis showed that the risk of dyslipidaemia begins to climb sharply once SUA exceeds 320 µmol/L. This suggests that for T2DM patients, "normal" uric acid levels might still be too high.
- Triglyceride Specificity: The association was strongest for hypertriglyceridaemia (OR 2.63) rather than high LDL or low HDL. This points toward a specific metabolic pathway involving SUA and triglyceride-rich lipoproteins.
- High Attributable Risk: In patients with hyperuricaemia, over 40% of their dyslipidaemia was statistically attributable to their elevated uric acid levels.
Key Results
- Primary Association: Hyperuricaemia was associated with a 3.72x increased risk of dyslipidaemia (95% CI: 2.28, 6.07) after adjusting for all potential confounders.
- Lipid Subtypes: Specifically, hyperuricaemia was linked to a 2.63x risk of hypertriglyceridaemia.
- Mediation Effect: The indirect effect of SUA in the insulin resistance-triglyceride pathway was significant ($p < 0.001$), explaining one-fifth of the total effect.
- Prevalence: In the hyperuricaemia group, the prevalence of dyslipidaemia was 78.5%, compared to 46.9% in the non-hyperuricaemia group.
Limitations and Future Work
- Causality: As a cross-sectional study, it captures a snapshot in time. It cannot definitively prove that high uric acid causes dyslipidaemia (though the mediation analysis provides a strong theoretical framework).
- Selection Bias: The study focused on hospitalised patients who generally had poorer glycaemic control (mean HbA1c ~9.3%) than the average T2DM patient, potentially limiting generalizability.
- Single Measurement: SUA and lipid levels were measured only once at admission, which may not reflect long-term fluctuations.
- Future Directions: The authors call for prospective randomized clinical trials to determine if aggressively lowering SUA (to targets below 320 µmol/L) can directly improve lipid profiles and reduce cardiovascular risk in diabetic populations.
Summary updated